Berenberg Bank Reaffirms Buy Rating for Advanced Medical Solutions Group (LON:AMS)

Advanced Medical Solutions Group (LON:AMS)‘s stock had its “buy” rating reissued by research analysts at Berenberg Bank in a research report issued on Wednesday, MarketBeat reports. They presently have a GBX 300 target price on the stock. Berenberg Bank’s price target suggests a potential upside of 48.15% from the company’s previous close.

Advanced Medical Solutions Group Price Performance

LON AMS opened at GBX 202.50 on Wednesday. The company has a 50-day moving average price of GBX 212.11 and a two-hundred day moving average price of GBX 214.30. Advanced Medical Solutions Group has a 52 week low of GBX 168.40 and a 52 week high of GBX 248.50. The stock has a market cap of £438.18 million, a price-to-earnings ratio of 48.56, a price-to-earnings-growth ratio of 5.00 and a beta of 0.60. The company has a current ratio of 2.79, a quick ratio of 4.58 and a debt-to-equity ratio of 31.50.

Advanced Medical Solutions Group (LON:AMS) last released its quarterly earnings results on Wednesday, March 18th. The company reported GBX 11.98 earnings per share for the quarter. Advanced Medical Solutions Group had a return on equity of 3.87% and a net margin of 4.35%. Analysts forecast that Advanced Medical Solutions Group will post 9.8159509 EPS for the current year.

About Advanced Medical Solutions Group

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label.